Mineralys files Form 144 to sell 3,000 shares

Mineralys Therapeutics reported a proposed sale of 3,000 shares of Common Stock under a Form 144 related to an exercise of employee stock options on 03/31/2026.

Accepted by SEC EDGAR 03/31/2026 - 04:18 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Mineralys Therapeutics reported a proposed sale of 3,000 shares of Common Stock under a Form 144 related to an exercise of employee stock options on 03/31/2026. The transaction is listed as a broker assisted cashless exercise through Merrill Lynch with aggregate value shown as $75,000.00.

Key Figures

Shares to be sold: 3,000 shares Aggregate value: $75,000.00 Reported outstanding figure: 82,399,478 +1 more

4 metrics

Shares to be sold 3,000 shares listed under Securities To Be Sold on 03/31/2026

Aggregate value $75,000.00 value associated with the 3,000 shares on 03/31/2026

Reported outstanding figure 82,399,478 numeric field present in the filing excerpt (03/31/2026)

Form date 03/31/2026 transaction and filing date shown in the excerpt

Key Terms

broker assisted cashless exercise, Form 144, exercise of employee stock options

3 terms

broker assisted cashless exercise financial

"Broker assisted cashless exercise"

Form 144 regulatory

"CONTENT METADATA: form_type: "144""

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

exercise of employee stock options financial

"Exercise of employee stock options"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Mineralys Therapeutics (MLYS) Form 144 disclose?

The Form 144 discloses a proposed sale of 3,000 shares tied to an employee option exercise on 03/31/2026. It lists a broker assisted cashless exercise and shows an aggregate value of $75,000.00.

Who handled the transaction listed on the MLYS Form 144?

The filing lists Merrill Lynch as the broker handling the transaction at its New York address. The sale method is recorded as a broker assisted cashless exercise executed on 03/31/2026.

How many shares and what value are shown on the MLYS Form 144?

The Form 144 shows 3,000 shares proposed for sale with an aggregate value of $75,000.00, and the transaction date recorded as 03/31/2026 under the cashless exercise method.

Does the Form 144 indicate the reason for the sale for MLYS?

Yes. The filing ties the sale to an exercise of employee stock options. The method is described as a broker assisted cashless exercise, indicating options were exercised and shares sold to cover costs and taxes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001816952
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Mineralys Therapeutics, Inc.
SEC File Number	001-41614
Address of Issuer	150 N. RADNOR CHESTER RD. SUITE F200 RADNOR PENNSYLVANIA 19087
Phone	(888) 378-6240
Name of Person for Whose Account the Securities are To Be Sold	Karydas Daphne
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	3000	75000.00	82399478	03/31/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/31/2026	Exercise of employee stock options	Mineralys Therapeutics, Inc.			3000	03/31/2026	Broker assisted cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	03/31/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/22/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Daphne Karydas
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)